Analysts have revised Shilpa Medicare’s fair value price target substantially downward from ₹1,028.50 to ₹514.25. This change reflects updated projections and a reassessment of expected performance metrics.
What's in the News
- Shilpa Medicare secures the world's first regulatory approval from India's CDSCO for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, targeting NAFLD. The company aims for rapid commercialization in India and international expansion. (Key Developments)
- Announces a 2:1 stock split or significant stock dividend, effective October 3, 2025. (Key Developments)
- Board meeting scheduled for August 13, 2025, with agenda items including approval of unaudited Q1 financials, re-appointments of top executives, proposal for bonus shares, and other key business matters. (Key Developments)
- Shilpa Medicare's biologics arm becomes exclusive global development and manufacturing partner for Alveolus Bio through a strategic financing round. This supports the advancement of innovative respiratory therapeutics. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has fallen significantly from ₹1,028.50 to ₹514.25, marking a substantial downward revision.
- Discount Rate remains unchanged at 12.73%.
- Revenue Growth projections are steady and nearly unchanged at approximately 23.55%.
- Net Profit Margin estimates show no material change and hold at around 24.95%.
- Future P/E ratio forecasts remain essentially constant at approximately 23.09x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.